This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Author: Avi Kapoor | September 17, 2025 08:15am

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Keybanc analyst Aleksey Yefremov initiated coverage on Avient Corporation (NYSE:AVNT) with an Overweight rating and announced a price target of $48. Avient shares closed at $35.77 on Tuesday. See how other analysts view this stock.
Barclays analyst Etzer Darout initiated coverage on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) with an Overweight rating and announced a price target of $72. Protagonist Therapeutics shares closed at $58.59 on Tuesday. See how other analysts view this stock.
Citigroup analyst Samantha Semenkow initiated coverage on Biohaven Ltd. (NYSE:BHVN) with a Buy rating and announced a price target of $28. Biohaven shares closed at $13.49 on Tuesday. See how other analysts view this stock.
Barclays analyst Etzer Darout initiated coverage on Summit Therapeutics Inc. (NASDAQ:SMMT) with an Underweight rating and announced a price target of $13. Summit Therapeutics shares closed at $18.12 on Tuesday. See how other analysts view this stock.
Bernstein analyst Zhihan Ma initiated coverage on Five Below, Inc. (NASDAQ:FIVE) with a Market Perform rating and announced a price target of $160. Five Below shares closed at $149.06 on Tuesday. See how other analysts view this stock.